Showing results (1-10 of 101) with videos related to

Sort By:
Pageof 11
Cancer Biology & Therapy|June 2, 2009
Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabineWan-Ling Sun, Georg Hutarew, Johann Gradl, et al.
Journal of Palliative Medicine|June 30, 2011
Quality of life trajectory in patients with advanced cancer during the last year of lifeJohannes M Giesinger, Lisa M Wintner, Anne S Oberguggenberger, et al.
Current Opinion in Pulmonary Medicine|June 2, 2005
The utility of fluorescence in-situ hybridization in the diagnosis of malignant pleural effusionMichael Fiegl
Experimental Hematology|April 28, 2016
Microenvironmental oxygen partial pressure in acute myeloid leukemia: Is there really a role for hypoxia?Christina T Rieger, Michael Fiegl
Clinical Chemistry and Laboratory Medicine|April 29, 2009
Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometryMagdalena Ligor, Tomasz Ligor, Amel Bajtarevic, et al.
Medizinische Klinik (Munich, Germany : 1983)|April 12, 2007
[Current therapeutic strategies in the management of acute myeloid leukemia]Michael Fiegl, Wolfgang Hiddemann, Jan Braess
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology|March 24, 2012
Prognostic and predictive value of cell cycle deregulation in non-small-cell lung cancerWilliam Sterlacci, Michael Fiegl, Alexandar Tzankov
Cancer Research|March 5, 2009
Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolismIsmael Samudio, Michael Fiegl, Michael Andreeff
Applied Immunohistochemistry & Molecular Morphology : AIMM|May 7, 2019
Cluster Analysis According to Immunohistochemistry is a Robust Tool for Non-Small Cell Lung Cancer and Reveals a Distinct, Immune Signature-defined SubgroupWilliam Sterlacci, Michael Fiegl, Darius Juskevicius, et al.
Annals of Hematology|November 2, 2004
A phase I/II study of oral etoposide and idarubicin in elderly patients with high-risk acute myeloid leukemia unable to undergo intensive chemotherapyMichael Fiegl, Thomas Büchner, Wolfgang Hiddemann, et al.
Pageof 11